The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience


Creative Commons License

Danis N., Pullukcu H., Yamazhan T., Ersoz G., ÜNAL N. G., Gunsar F., ...More

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.25, no.3, pp.109-112, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.4274/vhd.galenos.2019.2019.0028
  • Journal Name: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.109-112
  • Keywords: Hepatitis C virus, Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir, haemodialysis, VIRUS-INFECTION, COMBINATION
  • Dokuz Eylül University Affiliated: No

Abstract

Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients.